{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-019909","form_type":"8-K","ticker":"CRVO","cik":"0001053691","company_name":"CervoMed Inc.","filed_at":"2026-06-09T10:02:03+00:00","discovered_at":"2026-06-09T10:10:00.286857+00:00","generated_at":"2026-06-09T10:11:25.983862+00:00","sec_items":["5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"confidence":"high","headline":"CervoMed stockholders approve all four proposals at 2026 annual meeting","bullets":["Elected eight directors with 3.1M+ votes for each; broker non-votes of ~3.0M on each.","Ratified RSM US LLP as auditor for FY 2026: 6,092,751 for, 21,433 against.","Approved advisory say-on-pay for named executive officers: 3,073,013 for, 104,221 against.","Approved Amendment No. 1 to 2025 Equity Incentive Plan: 3,044,744 for, 132,860 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019909","json":"https://secwatch.observer/filing/0001437749-26-019909.json","markdown":"https://secwatch.observer/filing/0001437749-26-019909.md","text":"https://secwatch.observer/filing/0001437749-26-019909.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/0001437749-26-019909-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/crvo20260609_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T10:11:25.983862+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0b3e5b478ab7e57fa8d064be2a98d6c5e4f75c8d","claim":"CervoMed Inc. shareholders approved Election of eight directors at the 2026-06-08 meeting.","evidence_excerpt":"The election of each nominee pursuant to Proposal No. 1 required the affirmative vote of a plurality of the votes present and entitled to vote at the Annual Meeting and, accordingly, each nominee received the requisite number of votes for election at the Annual Meeting.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/0001437749-26-019909-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"1c153fc2c93a662710cc72a9432928f18809c44a","claim":"CervoMed Inc. shareholders approved Ratification of RSM US LLP as independent registered public accounting firm for 2026 at the 2026-06-08 meeting.","evidence_excerpt":"To ratify the selection of RSM US LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/0001437749-26-019909-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"634af66bea2dd03bed42d0fe621302777bc129c3","claim":"CervoMed Inc. shareholders approved Amendment No. 1 to the 2025 Equity Incentive Plan at the 2026-06-08 meeting.","evidence_excerpt":"To approve Amendment No. 1 to the CervoMed Inc. 2025 Equity Incentive Plan.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/0001437749-26-019909-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"},{"claim_id":"959bfa483716df2c906f30a04ee8eba0f51b1658","claim":"CervoMed Inc. shareholders approved Advisory approval of executive compensation for fiscal year 2024 at the 2026-06-08 meeting.","evidence_excerpt":"To approve, on an advisory basis, the compensation of the Company’s named executive officers during the year ended December 31, 2024, as disclosed in the Proxy Statement.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926019909/0001437749-26-019909-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-08"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}